Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin.
This paper dealt with improving the blood compatibility of the rapamycin-eluting stent by incorporating curcumin. The rapamycin- and rapamycin/curcumin-loaded PLGA (poly(d,l-lactic acid-co-glycolic acid)) coatings were fabricated onto the surface of the stainless steel stents using an ultrasonic atomization spray method. The structure of the coating films was characterized by Fourier transform infrared spectroscopy (FTIR). The optical microscopy and scanning electron microscopy (SEM) images of the drug-eluting stents indicated that the surface of all drug-eluting stents was very smooth and uniform, and there were not webbings and "bridges" between struts. There were not any cracks and delaminations on stent surface after expanded by the angioplasty balloon. The in vitro platelet adhesion and activation were investigated by static platelet adhesion test and GMP140 (P-selection), respectively. The clotting time was examined by activated partially prothromplastin time (APTT) test. The fibrinogen adsorption on the drug-loaded PLGA films was evaluated by enzyme-linked immunosorbent assay (ELISA). All obtained data showed that incorporating curcumin in rapamycin-loaded PLGA coating can significantly decrease platelet adhesion and activation, prolong APTT clotting time as well as decrease the fibrinogen adsorption. All results indicated that incorporating curcumin in rapamycin-eluting coating obviously improve the blood compatibility of rapamycin-eluting stents. It was suggested that it may be possible to develop a drug-eluting stent which had the characteristics of not only good anti-proliferation but also improved anticoagulation.
Pan
C J
CJ
Key Laboratory of Advanced Materials Technology, Education Ministry, Southwest Jiaotong University, Chengdu 610031, China.
Tang
J J
JJ
Shao
Z Y
ZY
Wang
J
J
Huang
N
N
D020341:Absorbable Implants; D000327:Adsorption; D015906:Angioplasty, Balloon, Coronary; D001769:Blood; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000517:prevention & control; D003474:Curcumin; D005340:Fibrinogen; D006801:Humans; D066298:In Vitro Techniques; D019344:Lactic Acid; D008422:Materials Testing; D008855:Microscopy, Electron, Scanning; D010973:Platelet Adhesiveness; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D020123:Sirolimus; D017550:Spectroscopy, Fourier Transform Infrared; D015607:Stents
D020099:Coated Materials, Biocompatible; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D005340:Fibrinogen; D003474:Curcumin; D020123:Sirolimus